RxDoctor Payments Data

Vanessa de Assis, PA

Surgical · Highlands Ranch, CONPI 1497221147

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 62 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$261
  • AbbVie$172
  • Boston Scientific$170
  • SRS Medical Systems, Inc.$167
  • Coloplast$146
  • Johnson & Johnson$81
  • plus $615 from 18 others

What the payments were for

  • Food & beverage$1,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 80th percentile of 495 surgical providers in Colorado.

See all surgical providers in Colorado

Medicare billing

Part B allowed, 2024
$28,984
Medicare patients
252
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron34$33,927
GemtesaVibegron27$19,961
Tamsulosin Hcl134$2,992
Potassium Citrate ErPotassium Citrate25$2,187
Solifenacin Succinate23$1,724
Methenamine Hippurate25$1,185
Finasteride41$988
Oxybutynin Chloride ErOxybutynin Chloride22$907
Alfuzosin Hcl ErAlfuzosin Hcl32$904
Cefpodoxime Proxetil25$451
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$362
CefuroximeCefuroxime Axetil15$115
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$75
Levofloxacin11$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$77$33,92734 claims
Sumitomo Pharma America, Inc.Gemtesa$261$19,96127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 495 surgical providers in Colorado.

Other surgical in Highlands Ranch

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →